Related Experiment Videos
Cost and quality trade-offs in the treatment of hypertension
1West Roxbury Veterans Administration Medical Center, Boston, Massachusetts.
Insights
Optimizing hypertension treatment cost-effectiveness involves targeting patients with high blood pressure and ensuring adherence. Lower-cost medications and prioritizing severe cases improve outcomes and reduce financial burdens.
Area of Science:
- Health Economics
- Cardiovascular Medicine
- Public Health
Background:
- Hypertension treatment cost-effectiveness is crucial for managing this chronic condition.
- Patient adherence and pretreatment blood pressure significantly influence treatment outcomes and economic viability.
- Inadequate insurance coverage, particularly for the poor, exacerbates cost challenges in hypertension management.
Purpose of the Study:
- To analyze the cost-effectiveness of hypertension treatment strategies.
- To identify factors influencing the economic viability of managing hypertension.
- To explore opportunities for improving the cost-effectiveness of hypertension care.
Main Methods:
- Comparative analysis of different hypertension treatment strategies.
- Evaluation of cost differences based on medication pricing and patient adherence.
- Assessment of the relationship between blood pressure levels and treatment cost-effectiveness.
Main Results:
- Treatment cost-effectiveness correlates positively with pretreatment blood pressure and patient adherence.
- Prioritizing patients with diastolic blood pressure ≥100 mm Hg and using lower-cost medications can enhance cost-effectiveness.
- For mild hypertension, initiating pharmacological treatment can vary by $270/patient-yr, influenced by side effects and medication costs.
Conclusions:
- Improving hypertension treatment cost-effectiveness involves targeted interventions and cost-conscious prescribing.
- The value of expensive treatments depends on demonstrable health benefits, balancing cost against efficacy.
- Addressing medication costs and insurance coverage is vital for equitable and effective hypertension management.
Abstract:
The cost-effectiveness of treatment for hypertension is positively related to the level of pretreatment blood pressure and to the level of success in achieving patient adherence to prescribed medical regimens. Opportunities to improve the cost-effectiveness of treatment include limiting treatment to patients with well-documented sustained increases in blood pressure, giving higher priority to the treatment of patients with diastolic blood pressures of 100 mm Hg and above, and relying on lower-cost medications if clinical responses to treatment permit. In patients with mild hypertension, a comparison of strategies for initiating pharmacological treatment that takes into account potential side effects as well as the costs of medications indicates a difference of $270/patient-yr between the least and most expensive alternatives. Whether the additional costs of more expensive treatment strategies are "worth it" depend on any additional health benefits actually conferred. Moreover, higher-cost strategies may have negative influences on patients' decisions to adhere to prescribed regimens or to continue in treatment. Cost is a particular problem for the treatment of chronic conditions like hypertension because of inadequate insurance coverage for medications, especially for the poor.